Wilmer Cutler Pickering Hale and Dorr advised Ratio Therapeutics Inc in the transaction. Ratio Therapeutics Inc, a pharmaceutical company, announced its exclusive worldwide license and collaboration...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Telix Pharmaceuticals Limited in the transaction. Telix Pharmaceuticals Limited (ASX: TLX) (Telix), a biopharmaceutical company, announced its acquisition of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Orna Therapeutics on the transaction. Orna Therapeutics, a biotechnology company, announced its acquisition of ReNAgade Therapeutics, a pioneer in...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Voyager Therapeutics on the deal. Voyager Therapeutics announced that it entered into a strategic collaboration agreement with Neurocrine Biosciences...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised ZebiAI Therapeutics, Inc. on the deal. ZebiAI Therapeutics, Inc., an artificial intelligence company that pioneers the application of machine...
You must be a Standard 1 Year member to access this content.
